[1. Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation During Immunosuppressive Drug Therapy. Gastroenterology. 2015 Jan 1;148(1):221–244.e3. DOI: 10.1053/j.gastro.2014.10.03810.1053/j.gastro.2014.10.038]Search in Google Scholar
[2. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017;67(2):370–98.]Search in Google Scholar
[3. Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatol Baltim Md. 2018;67(4):1560–99. DOI: 10.1002/hep.2980010.1002/hep.29800]Search in Google Scholar
[4. Davis GL, Hoofnagle JH, Waggoner JG. Spontaneous reactivation of chronic hepatitis B virus infection. Gastroenterology. 1984 Feb;86(2):230–5. DOI: 10.1016/0016-5085(84)90406-210.1016/0016-5085(84)90406-2]Search in Google Scholar
[5. Fattovich G, Brollo L, Alberti A, Realdi G, Pontisso P, Giustina G, et al. Spontaneous reactivation of hepatitis B virus infection in patients with chronic type B hepatitis. Liver. 1990 Jun;10(3):141–6. DOI: 10.1111/j.1600-0676.1990.tb00449.x10.1111/j.1600-0676.1990.tb00449.x]Search in Google Scholar
[6. Puri P. Acute Exacerbation of Chronic Hepatitis B: The Dilemma of Differentiation from Acute Viral Hepatitis B. J Clin Exp Hepatol. 2013 Dec;3(4):301–12. DOI: 10.1016/j.jceh.2013.08.01410.1016/j.jceh.2013.08.014]Search in Google Scholar
[7. Kazemi-Shirazi L, Petermann D, Müller C. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol. 2000 Nov;33(5):785–90. DOI: 10.1016/S0168-8278(00)80311-610.1016/S0168-8278(00)80311-6]Search in Google Scholar
[8. Yuen MF, Lee C, Wong D, Fung J, Hung I, Hsu A, et al. Prevalence of occult hepatitis B infection in a highly endemic area for chronic hepatitis B: a study of a large blood donor population. Gut. 2010 Oct 1;59:1389–93. DOI: 10.1136/gut.2010.20914810.1136/gut.2010.20914820675695]Search in Google Scholar
[9. Raimondo G, Locarnini S, Pollicino T, Levrero M, Zoulim F, Lok AS, et al. Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol. 2019 Aug;71(2):397–408. DOI: 10.1016/j.jhep.2019.03.03410.1016/j.jhep.2019.03.03431004683]Search in Google Scholar
[10. Makvandi M. Update on occult hepatitis B virus infection. World J Gastroenterol. 2016 Oct 21;22(39):8720–34. DOI: 10.3748/wjg.v22.i39.872010.3748/wjg.v22.i39.8720507554727818588]Search in Google Scholar
[11. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions. Gastroenterology. 2017 May;152(6):1297–309. DOI: 10.1053/j.gastro.2017.02.00910.1053/j.gastro.2017.02.009550198328219691]Search in Google Scholar
[12. Villadolid J, Laplant KD, Markham MJ, Nelson DR, George TJ. Hepatitis B reactivation and rituximab in the oncology practice. The Oncologist. 2010;15(10):1113–21. DOI: 10.1634/theoncologist.2010-010610.1634/theoncologist.2010-0106322789520930099]Search in Google Scholar
[13. Muraishi J, Shibata M, Honma Y, Hiura M, Abe S, Harada M. Reactivation of Occult Hepatitis B Virus Infection 27 Months after the End of Chemotherapy Including Rituximab for Malignant Lymphoma. Intern Med Tokyo Jpn. 2017;56(15):1967–71. DOI: 10.2169/internalmedicine.56.823310.2169/internalmedicine.56.8233557707128768965]Search in Google Scholar
[14. Tsutsumi Y, Yamamoto Y, Ito S, Ohigashi H, Shiratori S, Naruse H, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015 Sep 28;7(21):2344–51. DOI: 10.4254/wjh.v7.i21.234410.4254/wjh.v7.i21.2344457764226413224]Search in Google Scholar
[15. Sagnelli C, Pisaturo M, Calò F, Martini S, Sagnelli E, Coppola N. Reactivation of hepatitis B virus infection in patients with hemo-lymphoproliferative diseases, and its prevention. World J Gastroenterol. 2019 Jul 14;25(26):3299–312. DOI: 10.3748/wjg.v25.i26.329910.3748/wjg.v25.i26.3299663955031341357]Search in Google Scholar
[16. Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, et al. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014 Aug;63(8):1325–32. DOI: 10.1136/gutjnl-2013-30551710.1136/gutjnl-2013-30551724162593]Search in Google Scholar
[17. Matthews GV, Avihingsanon A, Lewin SR, Amin J, Rerknimitr R, Petcharapirat P, et al. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand. Hepatology. 2008;48(4):1062–9. DOI: 10.1002/hep.2246210.1002/hep.2246218697216]Search in Google Scholar
[18. Ueda Y, Marusawa H, Ichinohe T, Kadowaki N, Uchiyama T, Chiba T. Effective treatment for de novo hepatitis B with nucleotide analogue in patients with hematological malignancies. Am J Hematol. 2009 May;84(5):315–6. DOI: 10.1002/ajh.2138810.1002/ajh.2138819350661]Search in Google Scholar
[19. Sanchez MJ, Buti M, Homs M, Palacios A, Rodriguez-Frias F, Esteban R. Successful use of entecavir for a severe case of reactivation of hepatitis B virus following polychemotherapy containing rituximab. J Hepatol. 2009 Dec 1;51(6):1091–6. DOI: 10.1016/j. jhep.2009.07.012]Search in Google Scholar
[20. Brost S, Schnitzler P, Stremmel W, Eisenbach C. Entecavir as treatment for reactivation of hepatitis B in immunosuppressed patients. World J Gastroenterol WJG. 2010 Nov 21;16(43):5447–51. DOI: 10.3748/wjg.v16. i43.5447]Search in Google Scholar
[21. Nagaoka S, Abiru S, Komori A, Sasaki R, Bekki S, Hashimoto S, et al. Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long-term follow-up study. Hepatol Res. 2016;46(3):E89–99. DOI: 10.1111/hepr.1253310.1111/hepr.1253325951079]Search in Google Scholar
[22. Buti M, Riveiro-Barciela M, Esteban R. Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver Int. 2018;38(S1):84–9. DOI: 10.1111/liv.1364110.1111/liv.1364129427500]Search in Google Scholar
[23. Popescu C, Lobodan A, Rădulescu M, Negru A, Molagic V, Hristea A, et al. Treatment of chronic HBV hepatitis - between immune control and virological control. BMC Infect Dis. 2014 Oct 15;14(7):O10. DOI: 10.1186/1471-2334-14-S7-O1010.1186/1471-2334-14-S7-O10]Search in Google Scholar
[24. Aydemir S, Yildirmak MT, Sayan M, Atak S, Kucuk M. A chronic hepatitis B patient infected with HBsAg diagnostic-escape strain in the presence of anti-HBs positivity. Rev Romana Med Lab. 2019;27(4):421–6. DOI:10.2478/rrlm-2019-003810.2478/rrlm-2019-0038]Search in Google Scholar